Articles tagged "Cytomeglovirus"

2018 American Transplant Congress
Transplantation Tolerance Prevents CMV Reactivation and Preserves Kidney Allograft Function in a D+/R- Transplant Setting
A. Dangi,¹ J-.J. Wang,² M. Burnette,¹ Z. Zhang,² X. Luo.^1,2
¹Division of Nephrology and Hypertension, Department of Medicine, Northwestern University, Chicago, IL; ²Comprehensive Transplant Center, Department of Surgery, Northwestern University, Chicago, IL.
Background: Immune responses to cytomegalovirus (CMV) infection may precipitate acute/chronic graft rejection in immunocompromised transplant recipients. CMV infection can be primary or its reactivation from…
2018 American Transplant Congress
High Grade Cytomegalovirus Viremia Events in Solid Organ Transplant Recipients: Description and Quality Improvement
M. Spinner,¹ V. Athans,¹ C. Koval.²
¹Dept. of Pharmacy, Cleveland Clinic, Cleveland, OH; ²Dept. of Infectious Diseases, Cleveland Clinic, Cleveland, OH.
Background: High grade cytomegalovirus viremia (HGCMVV) often results in symptomatic disease requiring IV antiviral therapy and is associated with CMV recurrence and resistance. We postulated…
2018 American Transplant Congress
Ten Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients
S. El Hajj, J. Azzi, M. Kim, S. Gabardi.
Pharmacy, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; Kidney Transplant, Brigham and Women's Hospital, Boston; Kidney Transplant, Brigham and Women's Hospital, Boston.
Introduction: Cytomegalovirus (CMV) remains one the most clinically relevant and frequent post-transplant infections. Despite the availability of effective antiviral drugs, CMV continues to be of…
2018 American Transplant Congress
Macrophage Depletion of RCMV-Latently Infected Allografts Ameliorates Accelerated Chronic Cardiac Rejection
J. Burg,¹ N. Haese,² T. Andoh,² C. Kreklywich,² I. Jones,² S. Orloff,¹ D. Streblow.²
¹Abdominal Organ Transplantation, OHSU, Portland, OR; ²VGTI, OHSU, Portland, OR.
PurposeLatent donor rat cytomegalovirus (RCMV) infection accelerates chronic rejection (CR) in a heterotopic rat heart transplant model. RCMV latency is associated with an influx of…
2018 American Transplant Congress
Mayo Clinic's First Face Transplant: 17 Months On
H. Amer, S. Jowsey-Gregoire, C. Rosen, R. Razonable, K. Reid, M. Gandhi, L. Ewoldt, B. Edwards, S. Mardini.
The Essam and Dalal Obaid Reconstructive Transplant Center and the William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN.
Mayo Clinic established a reconstructive transplant program as an extension of clinical practice in 2010. A 31-year-old Caucasian male had significant functional limitations and disfigurement…
2018 American Transplant Congress
Defective Innate Immune Response to Opportunistic Pathogens in Cytomegalovirus-Infected Monocytes
P. Sen, A. R. Wilkie, R. Fernandes, R. J. Lane, S. E. Hickman, T. K. Means, E. R. Rosenberg, D. M. Coen, J. A. Fishman, J. El Khoury.
Transplant and Immunocompromised Group, Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA; Department of Biological Chemistry and Pharmacology, Harvard Medical School, Boston, MA.
Human cytomegalovirus (CMV) is the most common infection encountered in transplantation and is an important cause of morbidity and mortality in both solid organ and…
2018 American Transplant Congress
Pneumocystis jiroveci Pneumonia (PJP) in Kidney and Pancreas Transplant Recipients in the Present Era of Routine Post-Transplant Prophylaxis: Risk Factors and Outcomes
N. Garg, M. Jorgenson, M. Birschbach, J. Descourouez, S. Parajuli, B. Astor, A. Djamali, D. Mandelbrot.
University of Wisconsin, Madison.
PJP after transplant (TX) is associated with substantial morbidity and mortality. In the present era of universal and routine implementation of PJP prophylaxis (PPX) during…
2018 American Transplant Congress
NKG2C+CD57+ NK (G2C+57+) Cells Expanded by CMV Infection Are Highly Responsive to Allo-Antibody (Ab)-Mediated NK Cell Stimulation
B. Shin,¹ D. Puliyanda,² H. Pizzo,² S. Jordan,² M. Toyoda.¹
¹Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA; ²Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Active CMV infection is known to be associated with risk for ABMR in allograft recipients. Ab-dependent cellular cytotoxicity (ADCC) primarily mediated by NK cells…
2018 American Transplant Congress
Viral-Specific Cytotoxic T-Cell (Viral-Tc) Responses in Highly-HLA-Sensitized Patients (HS) Maintained on Tacrolimus and Everolimus Post-HLAi Kidney Transplant
S. Ge,¹ M. Chu,¹ A. Karasyov,¹ D. Lovato,¹ J. Kahwaji,² A. Vo,¹ J. Choi,¹ S. Louie,¹ S. Jordan,¹ M. Toyoda.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Kidney Transplantation, Kaiser Permanente Medical Center, Los Angeles, CA.
Introduction: Viral infections represent significant infectious complications post- kidney transplant which may be increased with desensitization. CMV, EBV and BKV infections are the most prevalent.…
2018 American Transplant Congress
CMV and BKV Infections after Kidney Transplantation: Combined Tacrolimus/everolimus Strategy Using Antithymocyte Globulin Induction
T. Jouve,^1,4 R. Germi,^2,4 B. Janbon,¹ G. Fiard,^3,4 P. Malvezzi,¹ L. Rostaing.^1,4
¹Nephrology, Dialysis, Apheresis, Transplantation Unit, Grenoble University Hospital, Grenoble, France; ²Virology Unit, Grenoble University Hospital, Grenoble, France; ³Urology Unit, Grenoble University Hospital, Grenoble, France; ⁴Medical Sciences, Grenoble University, Grenoble, France.
Cytomegalovirus (CMV) and BK Virus (BKV) infections are frequent complications after kidney transplantation. A combined regimen of calcineurin inhibitor (CNI) and mTOR inhibitors (mTORi) reduces…